We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Labcorp Prepares to Report Q3 Earnings: What's in the Cards?
Read MoreHide Full Article
Key Takeaways
Labcorp's Q3 revenues are projected to rise 5.7% to $3.77 billion, with EPS expected to grow 11.2%.
Strong testing volumes, acquisitions and specialty testing expansion may drive 6% Dx revenue growth.
Labcorp's BLS revenues may grow 3.9%, supported by Central Laboratories and the MLM acquisition.
Labcorp Holdings Inc. (LH - Free Report) is slated to report its third-quarter 2026 results on Oct. 28, before the market opens.
In the last reported quarter, the company posted adjusted earnings per share (EPS) of $4.99, surpassing the Zacks Consensus Estimate by 4.18%. Labcorp outpaced estimates in each of the trailing four quarters, the average surprise being 3.09%.
Q3 Estimates for LH
The Zacks Consensus Estimate for Labcorp’s third-quarter 2026 revenues is pegged at $3.77 billion. This suggests a 5.7% rise from the year-ago reported figure.
The Zacks Consensus Estimate for third-quarter EPS indicates an improvement of 11.2% to $4.65. The estimate has remained unchanged in the past 30 days.
Here's a quick review of the company’s performance leading up to its third-quarter earnings.
What Could Shape Labcorp's Q3 Results?
In the third quarter of 2026, Diagnostics Laboratories (“Dx”) segment’s performance is likely to have benefited from continued organic growth, supported by strong testing volumes and increasing tests per accession.
Labcorp is expected to have benefited from its ongoing expansion through health system partnerships and laboratory acquisitions, strengthening its patient and provider network and supporting testing demand. In the previous quarter, Labcorp’s acquisition of select outreach laboratory services from Parkview Health in Indiana and Ohio, along with Tribal Diagnostics in Oklahoma and Texas, is expected to have supported third-quarter sales growth.
Additionally, strategic collaborations with the National Association of Community Health Centers and OHSU’s Knight Cancer Institute, along with an agreement with the Defense Health Agency to continue providing clinical reference laboratory services to the Military Health System, are expected to have strengthened Labcorp’s market presence and growth prospects.
The company’s expanding specialty testing portfolio likely remained another tailwind. These tests are focused on the areas spanning oncology, women's health, neurology and autoimmune disease, which are projected to far outpace the broader diagnostics market.
In the third quarter of 2026, Labcorp Oncology’s performance is likely to have benefited from portfolio expansion across lung, colorectal and prostate cancer. This is supported by the nationwide launch of ColoSense, an RNA-based colorectal cancer screening test with an at-home collection, and the addition of advanced DPYD genotyping testing, which helps identify patients at risk for severe treatment-related toxicity from certain chemotherapies. Additionally, in August, the nationwide availability of Roche’s FDA-approved VENTANA PTEN (SP218) RxDx Assay, which helps identify prostate cancer patients eligible for treatment with AstraZeneca’s TRUQAP-based combination therapy, is expected to have further strengthened the company’s oncology testing portfolio.
In the third quarter of 2026, Labcorp OnDemand’s revenues are expected to have benefited from strong demand for consumer health tests, supported by the expansion of its direct-to-consumer testing portfolio. The introduction of the Marker by Labcorp Genetic Health Panel, offering integrated biomarker and genetic testing insights, along with the launch of at-home self-collection tests for fertility-related hormones and testosterone levels in Canada, is likely to have further supported growth.
Labcorp is also expected to have benefited from its continued adoption of advanced technologies, including AI and robotics, to enhance customer experiences and operational efficiency. The growing adoption of its recently launched AI-powered MyLabcorp app, which has already attracted millions of downloads, is likely to have further supported customer engagement and productivity.
The Zacks Consensus Estimate expects Dx revenues to grow 6% year over year.
Within the Biopharma Laboratory Services (“BLS”) segment, Labcorp is likely to have benefited from the solid performance of Central Laboratories. The company may have also progressed with its strategic actions to streamline the Early Development business, which may have limited overall growth.
During the third quarter, Labcorp acquired MLM Medical Labs (“MLM”), a leading global central and specialty laboratory provider. The acquisition strengthens Labcorp’s global presence and biomarker testing capabilities, establishing a wholly owned laboratory network across North America, Europe, Asia and Africa.
The Zacks Consensus Estimate suggests that BLS revenues will grow 3.9% year over year.
Q3 Earnings Whispers for Labcorp
Per our proven model, stocks with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP, have a higher chance of beating estimates, which is not the case here, as you can see below:
LH’s Earnings ESP: Labcorp has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Here are some medical stocks worth considering, as these have the right combination of elements to post an earnings beat this time:
TG Therapeutics (TGTX - Free Report) has an Earnings ESP of +71.43% and a Zacks Rank #1 at present. The company is expected to release third-quarter 2026 results soon.
TGTX’s earnings beat estimates in one of the trailing four quarters and missed on the remaining three occasions, the average surprise being 184.65%. The Zacks Consensus Estimate for third-quarter EPS implies a decrease of 84.8% from the year-ago quarter’s figure.
Revvity (RVTY - Free Report) has an Earnings ESP of +1.03% and a Zacks Rank #2 at present. The company is slated to release third-quarter 2026 results on Nov. 3.
RVTY’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 6.59%. The Zacks Consensus Estimate for third-quarter EPS indicates an increase of 9.3% from the year-ago quarter’s figure.
Acadia Healthcare (ACHC - Free Report) has an Earnings ESP of +4.84% and a Zacks Rank #3 at present. The company is slated to release third-quarter results on Nov. 4.
ACHC’s earnings surpassed estimates in all of the trailing four quarters, the average surprise being 47.02%. The Zacks Consensus Estimate for third-quarter EPS calls for a decrease of 36.1% from the year-ago quarter’s figure.
View the Zacks #1 Rank List
Image: Bigstock
Labcorp Prepares to Report Q3 Earnings: What's in the Cards?
Key Takeaways
Labcorp Holdings Inc. (LH - Free Report) is slated to report its third-quarter 2026 results on Oct. 28, before the market opens.
In the last reported quarter, the company posted adjusted earnings per share (EPS) of $4.99, surpassing the Zacks Consensus Estimate by 4.18%. Labcorp outpaced estimates in each of the trailing four quarters, the average surprise being 3.09%.
Q3 Estimates for LH
The Zacks Consensus Estimate for Labcorp’s third-quarter 2026 revenues is pegged at $3.77 billion. This suggests a 5.7% rise from the year-ago reported figure.
The Zacks Consensus Estimate for third-quarter EPS indicates an improvement of 11.2% to $4.65. The estimate has remained unchanged in the past 30 days.
Here's a quick review of the company’s performance leading up to its third-quarter earnings.
What Could Shape Labcorp's Q3 Results?
In the third quarter of 2026, Diagnostics Laboratories (“Dx”) segment’s performance is likely to have benefited from continued organic growth, supported by strong testing volumes and increasing tests per accession.
Labcorp is expected to have benefited from its ongoing expansion through health system partnerships and laboratory acquisitions, strengthening its patient and provider network and supporting testing demand. In the previous quarter, Labcorp’s acquisition of select outreach laboratory services from Parkview Health in Indiana and Ohio, along with Tribal Diagnostics in Oklahoma and Texas, is expected to have supported third-quarter sales growth.
Additionally, strategic collaborations with the National Association of Community Health Centers and OHSU’s Knight Cancer Institute, along with an agreement with the Defense Health Agency to continue providing clinical reference laboratory services to the Military Health System, are expected to have strengthened Labcorp’s market presence and growth prospects.
The company’s expanding specialty testing portfolio likely remained another tailwind. These tests are focused on the areas spanning oncology, women's health, neurology and autoimmune disease, which are projected to far outpace the broader diagnostics market.
In the third quarter of 2026, Labcorp Oncology’s performance is likely to have benefited from portfolio expansion across lung, colorectal and prostate cancer. This is supported by the nationwide launch of ColoSense, an RNA-based colorectal cancer screening test with an at-home collection, and the addition of advanced DPYD genotyping testing, which helps identify patients at risk for severe treatment-related toxicity from certain chemotherapies. Additionally, in August, the nationwide availability of Roche’s FDA-approved VENTANA PTEN (SP218) RxDx Assay, which helps identify prostate cancer patients eligible for treatment with AstraZeneca’s TRUQAP-based combination therapy, is expected to have further strengthened the company’s oncology testing portfolio.
In the third quarter of 2026, Labcorp OnDemand’s revenues are expected to have benefited from strong demand for consumer health tests, supported by the expansion of its direct-to-consumer testing portfolio. The introduction of the Marker by Labcorp Genetic Health Panel, offering integrated biomarker and genetic testing insights, along with the launch of at-home self-collection tests for fertility-related hormones and testosterone levels in Canada, is likely to have further supported growth.
Labcorp is also expected to have benefited from its continued adoption of advanced technologies, including AI and robotics, to enhance customer experiences and operational efficiency. The growing adoption of its recently launched AI-powered MyLabcorp app, which has already attracted millions of downloads, is likely to have further supported customer engagement and productivity.
The Zacks Consensus Estimate expects Dx revenues to grow 6% year over year.
Labcorp Holdings Inc. Price and EPS Surprise
Labcorp Holdings Inc. price-eps-surprise | Labcorp Holdings Inc. Quote
Within the Biopharma Laboratory Services (“BLS”) segment, Labcorp is likely to have benefited from the solid performance of Central Laboratories. The company may have also progressed with its strategic actions to streamline the Early Development business, which may have limited overall growth.
During the third quarter, Labcorp acquired MLM Medical Labs (“MLM”), a leading global central and specialty laboratory provider. The acquisition strengthens Labcorp’s global presence and biomarker testing capabilities, establishing a wholly owned laboratory network across North America, Europe, Asia and Africa.
The Zacks Consensus Estimate suggests that BLS revenues will grow 3.9% year over year.
Q3 Earnings Whispers for Labcorp
Per our proven model, stocks with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP, have a higher chance of beating estimates, which is not the case here, as you can see below:
LH’s Earnings ESP: Labcorp has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Labcorp's Zacks Rank: The company currently carries a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.
Key MedTech Picks
Here are some medical stocks worth considering, as these have the right combination of elements to post an earnings beat this time:
TG Therapeutics (TGTX - Free Report) has an Earnings ESP of +71.43% and a Zacks Rank #1 at present. The company is expected to release third-quarter 2026 results soon.
TGTX’s earnings beat estimates in one of the trailing four quarters and missed on the remaining three occasions, the average surprise being 184.65%. The Zacks Consensus Estimate for third-quarter EPS implies a decrease of 84.8% from the year-ago quarter’s figure.
Revvity (RVTY - Free Report) has an Earnings ESP of +1.03% and a Zacks Rank #2 at present. The company is slated to release third-quarter 2026 results on Nov. 3.
RVTY’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 6.59%. The Zacks Consensus Estimate for third-quarter EPS indicates an increase of 9.3% from the year-ago quarter’s figure.
Acadia Healthcare (ACHC - Free Report) has an Earnings ESP of +4.84% and a Zacks Rank #3 at present. The company is slated to release third-quarter results on Nov. 4.
ACHC’s earnings surpassed estimates in all of the trailing four quarters, the average surprise being 47.02%. The Zacks Consensus Estimate for third-quarter EPS calls for a decrease of 36.1% from the year-ago quarter’s figure.